持続性モルヒネ坐剤による末期がん患者の疼痛管理

概要

論文の詳細を見る
The morphine preparations, which have the rapid initial absorption and the subsequent prolonged absorption simultaneously, are desired to manage the pain of the terminal cancer patients. The clinical analgesic and sedative effects and the side effects of a slow release morphine hydrochloride-sodium alginate suppository, MA suppository, were evaluated in the cancer inpatients and outpatients. The MA suppository analgesia appeared with in 20 minutes after rectal administration, regardless of the intensity of the initial pain of the patients. Of 17 cancer patients, nine patients and six patients required the MA suppository every 24 hours and 12 hours for optimal analgesia, respectively. No clinical problem in transition sedation was observed by use of MA suppository from the view point of quality of life for the patients. The extent of the other side effects is vanishingly mild, and then the administration of the suppository to the patients could be continued to their dying day. MA suppository is very safe and useful to care for a cancer patient at home.
日本医療薬学会の論文